BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9062138)

  • 21. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
    Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
    Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
    Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
    Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients.
    Alvarez RD; Curiel DT
    Hum Gene Ther; 1997 Jan; 8(2):229-42. PubMed ID: 9017426
    [No Abstract]   [Full Text] [Related]  

  • 26. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.
    Kim J; Hwang ES; Kim JS; You EH; Lee SH; Lee JH
    Cancer Gene Ther; 1999; 6(2):172-8. PubMed ID: 10195884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
    Song K; Cowan KH; Sinha BK
    Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.
    Kelly FJ; Miller CR; Buchsbaum DJ; Gomez-Navarro J; Barnes MN; Alvarez RD; Curiel DT
    Clin Cancer Res; 2000 Nov; 6(11):4323-33. PubMed ID: 11106250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir.
    Rosenfeld ME; Feng M; Michael SI; Siegal GP; Alvarez RD; Curiel DT
    Clin Cancer Res; 1995 Dec; 1(12):1571-80. PubMed ID: 9815958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
    Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
    Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adenovirus mediated angiostatin gene therapy for ovarian cancer: experiment with nude mice].
    Jia CR; Yang SY; Han SY; Sun L
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(31):2204-8. PubMed ID: 19080673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
    Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
    Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.
    Deshane J; Grim J; Loechel S; Siegal GP; Alvarez RD; Curiel DT
    Cancer Gene Ther; 1996; 3(2):89-98. PubMed ID: 8729907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
    Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
    Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
    Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y; Shen K; Yu JR
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of protamine to augment adenovirus-mediated cancer gene therapy.
    Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
    Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.
    Xing X; Liu V; Xia W; Stephens LC; Huang L; Lopez-Berestein G; Hung MC
    Gene Ther; 1997 Mar; 4(3):238-43. PubMed ID: 9135737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy.
    Sanches R; Kuiper M; Penault-Llorca F; Aunoble B; D'Incan C; Bignon YJ
    Cancer Gene Ther; 2000 May; 7(5):707-20. PubMed ID: 10830718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
    Casado E; Gomez-Navarro J; Yamamoto M; Adachi Y; Coolidge CJ; Arafat WO; Barker SD; Wang MH; Mahasreshti PJ; Hemminki A; Gonzalez-Baron M; Barnes MN; Pustilnik TB; Siegal GP; Alvarez RD; Curiel DT
    Clin Cancer Res; 2001 Aug; 7(8):2496-504. PubMed ID: 11489832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.